AB314117

Anti-IGF1R (pY1161) + INSR (pY1185) + INSRR (pY1141) antibody [EPR26123-29] - BSA and Azide free

RabMAb
Recombinant
What is this?

Be the first to review this product! Submit a review

(0 Publication)

Rabbit Recombinant Monoclonal IGF1 Receptor phospho Y1161 antibody. Carrier free. Suitable for WB, Dot, IP and reacts with Human, Synthetic peptide samples.

View Alternative Names

CD221, Insulin-like growth factor 1 receptor, Insulin-like growth factor I receptor, IGF-I receptor, IGF1R, CD220, Insulin receptor, IR, INSR, IRR, INSRR, Insulin receptor-related protein, IR-related receptor

4 Images

Supplier Data

Immunoprecipitation - Anti-IGF1R (pY1161) + INSR (pY1185) + INSRR (pY1141) antibody [EPR26123-29] - BSA and Azide free (AB314117)

This data was developed using ab314116, the same antibody clone in a different buffer formulation. IGF1R (pY1161) + INSR (pY1185) + INSRR (pY1141) was immunoprecipitated from 0.35 mg HeLa starved for 18 hours, then treated with 100 ng/ml IGF-1 for 20 minutes whole cell lysate with ab314116 at 1/30 dilution (2ug in 0.35mg lysates). Western blot was performed on the immunoprecipitate using ab314116 at 1/1000 dilution. VeriBlot for IP secondary antibody(HRP)(ab131366) was used at 1/5000 dilution. Lane 1 : HeLa starved for 18 hours, then treated with 100 ng/ml IGF-1 for 20 minutes whole cell lysate Lane 2 : HeLa starved for 18 hours, then treated with 100 ng/ml IGF-1 for 20 minutes whole cell lysate Lane 3 : Rabbit monoclonal IgG (ab172730) instead of ab314116 in HeLa starved for 18 hours, then treated with 100 ng/ml IGF-1 for 20 minutes whole cell lysate Blocking and dilution buffer and concentration : 5% NFDM/TBST. Exposure time : 180 seconds

All lanes:

Immunoprecipitation - Anti-IGF1R (pY1161) + INSR (pY1185) + INSRR (pY1141) antibody [EPR26123-29] (<a href='/en-us/products/primary-antibodies/igf1r-py1161-insr-py1185-insrr-py1141-antibody-epr26123-29-ab314116'>ab314116</a>) at 1/30 dilution

All lanes:

HeLa starved for 18 hours, then treated with 100 ng/ml IGF-1 for 20 minutes whole cell lysate

Secondary

All lanes:

Immunoprecipitation - VeriBlot for IP Detection Reagent (HRP) (<a href='/en-us/products/reagents/veriblot-for-ip-detection-reagent-hrp-ab131366'>ab131366</a>) at 1/5000 dilution

false

Exposure time: 180s

Supplier Data

Western blot - Anti-IGF1R (pY1161) + INSR (pY1185) + INSRR (pY1141) antibody [EPR26123-29] - BSA and Azide free (AB314117)

This data was developed using ab314116, the same antibody clone in a different buffer formulation.

Blocking and diluting buffer and concentration : 5% NFDM/TBST.

This blot was developed using a high sensitivity ECL substrate. The high-sensitivity ECL substrate used allows for the detection of proteins in the mid-femtogram range.

In Western blot, Anti-GAPDH antibody [EPR16891] - Loading Control (ab181602) staining at 1/200000 dilution.

In Western blot, Anti-IGF1 Receptor antibody [EPR19322] (ab182408) staining at 1/1000 dilution.

All lanes:

Western blot - Anti-IGF1R (pY1161) + INSR (pY1185) + INSRR (pY1141) antibody [EPR26123-29] (<a href='/en-us/products/primary-antibodies/igf1r-py1161-insr-py1185-insrr-py1141-antibody-epr26123-29-ab314116'>ab314116</a>) at 1/1000 dilution

Lane 1:

HeLa (human cervix adenocarcinoma epithelial cell) starved for 18 hours whole cell lysate at 30 µg

Lane 2:

HeLa starved for 18 hours, then treated with 100ng/ml IGF-1 for 5 minutes whole cell lysate at 30 µg

Lane 3:

HeLa starved for 18 hours, then treated with 100ng/ml IGF-1 for 20 minutes whole cell lysate at 30 µg

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/100000 dilution

Observed band size: 100 kDa

true

Exposure time: 92s

Supplier Data

Western blot - Anti-IGF1R (pY1161) + INSR (pY1185) + INSRR (pY1141) antibody [EPR26123-29] - BSA and Azide free (AB314117)

This data was developed using ab314116, the same antibody clone in a different buffer formulation.

Blocking and diluting buffer and concentration : 5% NFDM/TBST.

This blot was developed using a high sensitivity ECL substrate. The high-sensitivity ECL substrate used allows for the detection of proteins in the mid-femtogram range.

In Western blot, Anti-IGF1 Receptor antibody [EPR19322] (ab182408) staining at 1/1000 dilution

All lanes:

Lane 1:

HeLa (human cervix adenocarcinoma epithelial cell) starved for 18 hours whole cell lysate (untreated membrane) at 30 µg

Lane 2:

HeLa starved for 18 hours, then treated with 100ng/mL IGF-1 for 10 minutes whole cell lysate (untreated membrane) at 30 µg

Lane 3:

HeLa starved for 18 hours whole cell lysate (alkaline phosphatase treated membrane) at 30 µg

Lane 4:

HeLa starved for 18 hours, then treated with 100ng/mL IGF-1 for 10 minutes whole cell lysate (alkaline phosphatase treated membrane) at 30 µg

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/100000 dilution

Observed band size: 100 kDa

true

Exposure time: 81s

Supplier Data

Dot Blot - Anti-IGF1R (pY1161) + INSR (pY1185) + INSRR (pY1141) antibody [EPR26123-29] - BSA and Azide free (AB314117)

This data was developed using ab314116, the same antibody clone in a different buffer formulation. Dot blot analysis of IGF1R (pY1161) + INSR (pY1185) + INSRR (pY1141) using ab314116 at 1 : 1000 (0.521 ug/ml) followed by a Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (ab97051) at 1 : 100,000 dilution. Lane 1 : IGF1 receptor (phospho Y1161)/Insulin receptor (phospho Y1185) peptide Lane 2 : IGF1 receptor/Insulin receptor non-phospho peptide Lane 3 : Insulin receptor-related protein (phospho Y1141) peptide Lane 4 : IGF1 receptor (phospho Y1165) peptide Lane 5 : IGF1 receptor (phospho Y1166) peptide Lane 6 : IGF1 receptor (phospho T1163) peptide Exposure time : 180 seconds Blocking and diluting buffer and concentration : 5% NFDM/TBST

Unconjugated

Anti-IGF1R (pY1161) + INSR (pY1185) + INSRR (pY1141) antibody [EPR26123-29]

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

EPR26123-29

Isotype

IgG

Carrier free

Yes

Reacts with

Human

Applications

IP, Dot, WB

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

Specificity

Based on dot blot data using peptides, this antibody reacts with IGF1 Receptor (phospho Y1161), Insulin receptor (phospho Y1185) and Insulin receptor-related protein (phospho Y1141).

style

left-column

style

left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "Dot" : {"fullname" : "Dot Blot", "shortname":"Dot"}, "IP" : {"fullname" : "Immunoprecipitation", "shortname":"IP"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"}, "FlowCyt" : {"fullname" : "Flow Cytometry", "shortname":"Flow Cyt"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "", "WB-species-notes": "", "Dot-species-checked": "guaranteed", "Dot-species-dilution-info": "", "Dot-species-notes": "", "IP-species-checked": "testedAndGuaranteed", "IP-species-dilution-info": "", "IP-species-notes": "", "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "", "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "", "FlowCyt-species-checked": "notRecommended", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "" }, "Mouse": { "WB-species-checked": "notRecommended", "WB-species-dilution-info": "", "WB-species-notes": "", "Dot-species-checked": "notRecommended", "Dot-species-dilution-info": "", "Dot-species-notes": "", "IP-species-checked": "notRecommended", "IP-species-dilution-info": "", "IP-species-notes": "", "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "", "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "", "FlowCyt-species-checked": "notRecommended", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "" }, "Rat": { "WB-species-checked": "notRecommended", "WB-species-dilution-info": "", "WB-species-notes": "", "Dot-species-checked": "notRecommended", "Dot-species-dilution-info": "", "Dot-species-notes": "", "IP-species-checked": "notRecommended", "IP-species-dilution-info": "", "IP-species-notes": "", "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "", "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "", "FlowCyt-species-checked": "notRecommended", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "" }, "Synthetic peptide": { "WB-species-checked": "notRecommended", "WB-species-dilution-info": "", "WB-species-notes": "", "Dot-species-checked": "testedAndGuaranteed", "Dot-species-dilution-info": "", "Dot-species-notes": "", "IP-species-checked": "notRecommended", "IP-species-dilution-info": "", "IP-species-notes": "", "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "", "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "", "FlowCyt-species-checked": "notRecommended", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "" } } }

style

left-column

Product details

ab314117 is the carrier-free version of ab314116.

Patented technology
Our RabMAb^® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb^® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production

For more information, read more on recombinant antibodies.

Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.

Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.

Compatibility
This product is compatible with the Maxpar^® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar^® is a trademark of Fluidigm Canada Inc.

style

left-column

Properties and storage information

Form

Liquid

Purification technique

Affinity purification Protein A

Storage buffer

pH: 7.2 - 7.4 Constituents: PBS

Shipped at conditions

Blue Ice

Appropriate short-term storage conditions

+4°C

Appropriate long-term storage conditions

+4°C

style

left-column

style

left-column

style

left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Visit the General protocols
Visit the Troubleshooting

style

left-column

Target data

Receptor tyrosine kinase which mediates actions of insulin-like growth factor 1 (IGF1). Binds IGF1 with high affinity and IGF2 and insulin (INS) with a lower affinity. The activated IGF1R is involved in cell growth and survival control. IGF1R is crucial for tumor transformation and survival of malignant cell. Ligand binding activates the receptor kinase, leading to receptor autophosphorylation, and tyrosines phosphorylation of multiple substrates, that function as signaling adapter proteins including, the insulin-receptor substrates (IRS1/2), Shc and 14-3-3 proteins. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways : the PI3K-AKT/PKB pathway and the Ras-MAPK pathway. The result of activating the MAPK pathway is increased cellular proliferation, whereas activating the PI3K pathway inhibits apoptosis and stimulates protein synthesis. Phosphorylated IRS1 can activate the 85 kDa regulatory subunit of PI3K (PIK3R1), leading to activation of several downstream substrates, including protein AKT/PKB. AKT phosphorylation, in turn, enhances protein synthesis through mTOR activation and triggers the antiapoptotic effects of IGFIR through phosphorylation and inactivation of BAD. In parallel to PI3K-driven signaling, recruitment of Grb2/SOS by phosphorylated IRS1 or Shc leads to recruitment of Ras and activation of the ras-MAPK pathway. In addition to these two main signaling pathways IGF1R signals also through the Janus kinase/signal transducer and activator of transcription pathway (JAK/STAT). Phosphorylation of JAK proteins can lead to phosphorylation/activation of signal transducers and activators of transcription (STAT) proteins. In particular activation of STAT3, may be essential for the transforming activity of IGF1R. The JAK/STAT pathway activates gene transcription and may be responsible for the transforming activity. JNK kinases can also be activated by the IGF1R. IGF1 exerts inhibiting activities on JNK activation via phosphorylation and inhibition of MAP3K5/ASK1, which is able to directly associate with the IGF1R.. When present in a hybrid receptor with INSR, binds IGF1. PubMed : 12138094 shows that hybrid receptors composed of IGF1R and INSR isoform Long are activated with a high affinity by IGF1, with low affinity by IGF2 and not significantly activated by insulin, and that hybrid receptors composed of IGF1R and INSR isoform Short are activated by IGF1, IGF2 and insulin. In contrast, PubMed : 16831875 shows that hybrid receptors composed of IGF1R and INSR isoform Long and hybrid receptors composed of IGF1R and INSR isoform Short have similar binding characteristics, both bind IGF1 and have a low affinity for insulin.

See full target information IGF1R pY1161

Additional targets

INSR phospho Y1185,INSRR phospho Y1141

style

left-column

style

left-column

style

right-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.

For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com

Anti-IGF1R (pY1161) + INSR (pY1185) + INSRR (pY1141) antibody [EPR26123-29] - BSA and Azide free

Immunoprecipitation - Anti-IGF1R (pY1161) + INSR (pY1185) + INSRR (pY1141) antibody [EPR26123-29] - BSA and Azide free (AB314117)

Western blot - Anti-IGF1R (pY1161) + INSR (pY1185) + INSRR (pY1141) antibody [EPR26123-29] - BSA and Azide free (AB314117)

Western blot - Anti-IGF1R (pY1161) + INSR (pY1185) + INSRR (pY1141) antibody [EPR26123-29] - BSA and Azide free (AB314117)

Dot Blot - Anti-IGF1R (pY1161) + INSR (pY1185) + INSRR (pY1141) antibody [EPR26123-29] - BSA and Azide free (AB314117)

Related conjugates and formulations (1)

Key facts

Host species

Clonality

Clone number

Isotype

Carrier free

Reacts with

Applications

Immunogen

Specificity

Complementary Products

Secondary Antibodies

Primary Antibodies

Assay Kits

Primary Antibodies

Reactivity data

Product details

Properties and storage information

Form

Purification technique

Storage buffer

Shipped at conditions

Appropriate short-term storage conditions

Appropriate long-term storage conditions

Product protocols

Target data

Additional targets

Product promise